MapLight Therapeutics (MPLT) Total Liabilities (2024 - 2026)
MapLight Therapeutics (MPLT) posted Total Liabilities of $21.1 million for Q4 2025, down 10.82% sequentially from $23.7 million in Q3 2025, and down 2.67% YoY from $21.7 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Total Liabilities (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Total Liabilities for 2 years, with the latest figure at $21.1 million in Q4 2025.
- Quarterly Total Liabilities fell 2.67% year-over-year to $21.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (down 2.67% YoY) and the FY2025 annual result came in at $21.1 million, down 2.67% from the prior year.
- Total Liabilities slipped to $21.1 million in Q4 2025 per MPLT's latest filing, from $23.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $23.7 million in Q3 2025 and troughed at $21.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | 20.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.05 Mn |
| Dec 31, 2025 | 21.14 Mn |
| Sep 30, 2025 | 23.71 Mn |
| Jun 30, 2025 | 245.06 Mn |
| Dec 31, 2024 | 21.72 Mn |
| Sep 30, 2024 | 172.37 Mn |